House Publications
The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
|
|
|
Notice PaperNo. 268 Thursday, December 14, 2023 10:00 a.m. |
|
|
|
|
Introduction of Government Bills |
|
Introduction of Private Members' Bills |
|
| December 13, 2023 — Mr. Davies (Vancouver Kingsway) — Bill entitled “An Act to amend the Canadian Environmental Protection Act, 1999 (electronic products recycling program)”. |
Notices of Motions (Routine Proceedings) |
|
Questions |
|
| Q-2158 — December 13, 2023 — Ms. Barron (Nanaimo—Ladysmith) — With regard to the conditions of licence for marine finfish aquaculture in British Columbia and the licence issued to Cermaq for its aquaculture farm at Bawden Point: (a) what were the dates of all licenses issued to Cermaq to operate its farm at Bawden Point since January 2015; (b) was Cermaq ever found in violation of the licenses it was issued and, if so, what are the reasons for breach of license; (c) were the licenses issued to Cermaq in (a) amended to allow for higher sea lice thresholds; (d) what are the details of all amendments in (c); and (e) was Cermaq fined or otherwise reprimanded for violations of the licenses it was issued? |
| Q-2159 — December 13, 2023 — Ms. Barron (Nanaimo—Ladysmith) — With regard to all federal funding committed to the creation and maintenance of housing stock in the federal electoral district of Nanaimo-Ladysmith, broken down by fiscal year since 2015-16: (a) what is the total amount committed, broken down by funding stream; (b) what was the total amount spent; (c) how much new housing stock was created in Nanaimo-Ladysmith; and (d) what are the government's projections on the number of housing units that will be built in Nanaimo-Ladysmith by 2030? |
| Q-2160 — December 13, 2023 — Mr. Desjarlais (Edmonton Griesbach) — With regard to federal spending in the constituency of Edmonton Griesbach, broken down by fiscal year and department or agency since 2021-22: what are the details of all grants and contributions and all loans to any organization, group, business or municipality, broken down by the (i) name of the recipient, (ii) date the funding was received, (iii) amount received, (iv) program under which the grant, contribution or loan was made? |
| Q-21612 — December 13, 2023 — Mr. Desjarlais (Edmonton Griesbach) — With regard to the social housing needs in the territories of the Yukon, Northwest Territories and Nunavut, since November 2015: (a) did the government conduct an audit in order to determine the social housing needs of each territory; (b) what were the results of each audit conducted in (a); (c) how does the government determine social housing needs in each territory; (d) how are social housing needs in (c) determined with respect to First Nations, Inuit, and Métis communities; (e) what mechanism does the government have in place to ensure that First Nations, Inuit and Métis social housing needs are addressed on an equitable basis; (f) what is the average age of social houses, broken down by territory; (g) how many houses have been constructed in each fiscal year, broken down by territory; (h) what is the average occupancy per social housing unit; and (i) how many social houses have been constructed per territory that are now deemed uninhabitable? |
| Q-21622 — December 13, 2023 — Mrs. Wagantall (Yorkton—Melville) — With regard to Health Canada’s use of preclinical manufacturer’s data for authorizing COVID-19 vaccines: (a) did Health Canada (HC), the Public Health Agency of Canada (PHAC) and the National Advisory Committee on Immunization (NACI) follow The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) standards; (b) were Developmental and Reproductive Toxicity (DART) guidelines required to be met for the determination of safety for either the Pfizer or the Moderna products for pregnant and lactating mothers; (c) if the answer to (b) is affirmative, (i) did the animal studies assess any effects within a complete reproductive cycle from conception to the reproductive capacity of the next generation, (ii) did the animal studies evaluate long term outcomes in offspring, (iii) were any fetal or offspring abnormalities detected, (iv) what fetal or offspring abnormalities were detected, (v) what is the significance of the fetal or offspring abnormalities in defining safety, (vi) were any adverse events observed in the mothers, (vii) what is the significance of adverse events observed in the mothers for human safety, (viii) was decreased fertility detected in the first or second generation, (ix) were biodistribution studies conducted in the pregnant animals and their fetuses, (x) were alternate routes of exposure studied in the animals including through mating with a vaccinated male or transmammary routes; (d) if the answer to (b) is negative, what requirements needed to be met with respect to DART prior to the interim order approval and after the interim approval? |
| Q-21632 — December 13, 2023 — Mrs. Wagantall (Yorkton—Melville) — With regard to Health Canada’s COVID-19 vaccine safety monitoring and assessment for pregnant and lactating (P&L) women: (a) are observational trials and surveillance systems adequate to establish safety or must this be accomplished through randomized trials; (b) were randomized control trials (RCTs) used to obtain approval and support safety claims in P&L women, and, if so, what are the details, including, the (i) name of the trial, (ii) date of the trial; (c) did the trials in (b) (i) include all trimesters, (ii) include high risk pregnancies, (iii) include clinical and sub-clinical testing, (iv) include a trial group measured against a placebo control group, (v) include a control group which remained intact for multiple years to establish long term safety data, (vi) be sufficiently powered to detect common and rare side-effects; (c) if the answer to (b) is negative, what trials were used to evaluate the safety in the P&L population prior to approval in this cohort, including the (i) trial name, (ii) trial date, (iii) analysis of the trial; (d) did Health Canada (HC), the Public Health Agency of Canada, the National Advisory Committee on Immunization or Canadian Institute for Health Information inform pregnant and lactating women of the Pfizer monograph “No data are available yet regarding the use of COMIRNATY Omicron XBB.1.5 during pregnancy” or “No data are available yet regarding the use of COMIRNATY Omicron XBB.1.5 during breast- feeding. It is unknown whether COMIRNATY Omicron XBB.1.5 is excreted in human milk. A risk to the newborns/infants cannot be excluded"; (e) if the answer to (d) is affirmative, how were pregnant and lactating women advised of the Pfizer safety data; (f) what is HC’s scientific basis for claiming safety of the XBB.1.5 mRNA product in P&L women; (g) what rigorous prospective studies, with active patient reporting and monitoring, is HC relying upon to support their safety claims in the P&L population for the use of Omicron XBB.1.5 product? |
| Q-21642 — December 13, 2023 — Ms. Zarrillo (Port Moody—Coquitlam) — With regard to the making of regulations for the Canada Disability Benefit: (a) what additional costs associated with living with a disability is the government taking into consideration when setting the amount of the benefit; (b) what are the average annual costs for persons with disabilities, both in dollars and as a percentage of disposable income, for (i) food, (ii) housing, (iii) medical expenses, (iv) assistive devices, (iv) transportation; (c) for the costs identified in (b), what are the average annual costs for persons without disabilities? |
| Q-21652 — December 13, 2023 — Ms. Zarrillo (Port Moody—Coquitlam) — With regard to the Freshwater Action Plan: (a) what is the total amount of funding committed, broken down by each priority watershed identified in the plan; (b) what is the total amount of funding, broken down by each priority watershed identified in the plan; (c) what is the total amount of funding spent for freshwater protection in British Columbia? |
| Q-21662 — December 13, 2023 — Ms. Zarrillo (Port Moody—Coquitlam) — With regard to the Disaster Financial Assistance Arrangements (DFAA) funding for British Columbia, from 2015 to 2023: (a) what is the total amount of funding committed, broken down by specific project; (b) what is the total amount of funding spent, broken down by specific project? |
| Q-21672 — December 13, 2023 — Ms. Zarrillo (Port Moody—Coquitlam) — With regard to the Disability Tax Credit, from 2020 to present, broken down by province and territory: (a) what is the average income for persons who receive the Disability Tax Credit (i) before tax, (ii) after tax; (b) what is the median income for persons who receive the Disability Tax Credit (i) before tax, (ii) after tax? |
| Q-21682 — December 13, 2023 — Mr. Epp (Chatham-Kent—Leamington) — With regard to the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 (the Interim Order) on September 16, 2020: (a) does the Minister of Health require an application by the manufacturer to approve a drug that is already approved for another indication; (b) what is the total number of inquiries received by Health Canada and the Public Health Agency of Canada about Ivermectin for the prophylaxis and treatment of COVID- 19; (c) how many inquiries have been made to Health Canada and the Public Health Agency of Canada about Ivermectin for the prophylaxis and treatment of COVID-19, broken down by (i) the general public (ii) healthcare clinicians, (iii) researchers, (iv) provincial and territorial health authorities, (v) hospitals, (vi) long-term care facilities, (vii) healthcare practitioners' regulatory governing bodies, (viii) Members of provincial, territorial and federal Parliament (ix) organizations; and (d) what is the number of signatures on any petitions related to Ivermectin? |
| Q-21692 — December 13, 2023 — Ms. Findlay (South Surrey—White Rock) — With regard to Canada’s vote at the United Nations on December 12, 2023 in favour of a ceasefire: (a) on what date was Ambassador Bob Rae instructed to vote in favour of a ceasefire, and who provided that instruction to the Ambassador; (b) which Jewish groups were consulted prior to the government making the decision and what feedback did they get; (c) if Jewish groups were not consulted about this vote prior to Canada taking this position, why were they not consulted; and (d) what is the government’s rationale for changing its longstanding position on Israel? |
| Q-21702 — December 13, 2023 — Ms. Findlay (South Surrey—White Rock) — With regard to the government’s supply and confidence agreement with the NDP and the associated universal, single payer pharmacare program: what are the government's projected costs to implement this program for 2024 and each of the following five years, broken down by year? |
| Q-21712 — December 13, 2023 — Mr. Cannings (South Okanagan—West Kootenay) — With regard to the administration of the Canada Emergency Business Account (CEBA) loan: (a) on what dates do existing contracts with Accenture Inc. for the administration of CEBA end; (b) has the government approached Accenture Inc. about extending contracts related to the administration of the CEBA program; (c) has Accenture Inc. informed the government that it will not be able to continue the administration of the CEBA program; (d) has the government approached any other management firms or corporations with a sole-source contract in order to continue the CEBA program; and (e) has the government done any evaluations or assessments of the ability for Export Development Canada or another government department or agency to operate the CEBA program beyond the current end date? |
| Q-21722 — December 13, 2023 — Mr. Cannings (South Okanagan—West Kootenay) — With regard to any polling data obtained by the Privy Council Office concerning policies affecting small and medium-sized businesses, since January 1, 2023: what are the details of all polling conducted, including (i) who conducted the poll, (ii) the start and end dates of when the poll was conducted, (iii) the number of participants, (iv) the questions asked, (v) the results of the poll, (v) the value of the contract related to the poll? |
| Q-21732 — December 13, 2023 — Mr. Cannings (South Okanagan—West Kootenay) — With regard to federal expenditures on wildland fire management for 2023, broken down by province and territory: (a) what are the total expenditures to date on wildland fire protection and suppression, including (i) fire preparedness, (ii) mitigation, (iii) response, (iv) recovery; and (b) what are the total anticipated expenditures on wildland fire protection and suppression, including (i) fire preparedness, (ii) mitigation, (iii) response, (iv) recovery? |
| Q-21742 — December 13, 2023 — Mr. Davies (Vancouver Kingsway) — With regard to diabetes and analysis done by Health Canada or relevant government departments: (a) does the government have an estimate of the total out-of-pocket costs that people in Canada have to pay on an annual basis if they do not have coverage for (i) prescription diabetes medication, (ii) insulin pumps, continuous glucose monitors and other diabetes control supplies, through public or private insurance? |
| Q-21752 — December 13, 2023 — Mr. Davies (Vancouver Kingsway) — With regard to the funding agreement with Prince Edward Island to improve affordable access to prescription drugs signed on August 11, 2021: (a) what are the details of all analyses done by the government that show greater access to prescription medications; (b) what indicators does the government use to show that individuals have greater access to prescription medications; and (c) what is the total number of individuals who have experienced improved access to prescription drug coverage? |
| Q-21762 — December 13, 2023 — Mr. Davies (Vancouver Kingsway) — With regard to the funding agreement with Prince Edward Island to improve affordable access to prescription drugs signed on August 11, 2021: (a) does the government have analyses on whether this initiative provides better access to prescription drugs when compared to (i) the recommendations of the Advisory Council on the Implementation of National Pharmacare, (ii) the Cost Estimate of a Single-payer Universal Drug Plan report issued by the Parliamentary Budget Officer on October 13, 2023; (b) what are the details of all analyses in (a); (c) does the government have analyses on whether this initiative would result in better cost savings compared to (i) the recommendations of the Advisory Council on the Implementation of National Pharmacare, (ii) the Cost Estimate of a Single-payer Universal Drug Plan report issued by the Parliamentary Budget Officer on October 13, 2023; and (d) what are the details of all analyses in (c)? |
| Q-21772 — December 13, 2023 — Mr. Boulerice (Rosemont—La Petite-Patrie) — With regard to any polling data obtained by the Privy Council Office, since January 1, 2023: (a) what are the details of all polling conducted, including (i) who conducted the poll, (ii) the start and end dates of when the poll was conducted, (iii) the number of participants, (iv) the topic or subject asked about, (v) the results of the poll, (vi) the value of the contract related to the poll? |
| Q-21782 — December 13, 2023 — Mr. Boulerice (Rosemont—La Petite-Patrie) — With regard to any polling data obtained by the Privy Council office concerning anti-scab legislation or replacement workers, since January 1, 2023: (a) what are the details of all polling conducted, including (i) who conducted the poll, (ii) the start and end dates of when the poll was conducted, (iii) the number of participants, (iv) the questions asked, (v) the results of the poll, (vi) the value of the contract related to the poll? |
| Q-21792 — December 13, 2023 — Mr. Boulerice (Rosemont—La Petite-Patrie) — With regard to any polling data obtained by the Privy Council Office concerning electoral reform, since January 1, 2023: (a) what are the details of all polling conducted, including (i) who conducted the poll, (ii) the start and end dates of when the poll was conducted, (iii) the number of participants, (iv) the questions asked, (v) the results of the poll, (vi) the value of the contract related to the poll? |
| Q-21802 — December 13, 2023 — Mrs. Hughes (Algoma—Manitoulin—Kapuskasing) — With regard to Translation Bureau operations, broken down by fiscal year since 2011-12: (a) what is the total number of hours that simultaneous interpretation was provided, broken down by (i) sittings of the House of Commons, (ii) meetings of House committees; (b) how many employees have provided simultaneous interpretation for (i) sittings of the house of Commons, (ii) meetings of House committees; (c) how many freelance contractors have provided simultaneous interpretation of (i) sittings of the House of Commons, (ii) meetings of House committees; and (d) what is the dollar value of all contracts related to (c)? |
| Q-21812 — December 13, 2023 — Mrs. Hughes (Algoma—Manitoulin—Kapuskasing) — With regard to Translation Bureau operations, broken down by House of Commons committee and fiscal year since 2011-12 to present: (a) what is the total number of requests submitted by each committee to the Translation Bureau for document translation; (b) what are the details of all requests in (a), including the (i) total number of pages requested, (ii) total number of hours to fulfill translation requests, (iii) total number of overtime hours required to fulfill translation requests, (iv) total cost to fulfill all requests? |
| Q-21822 — December 13, 2023 — Mrs. Hughes (Algoma—Manitoulin—Kapuskasing) — With regard to funding allocated through the Rapid Housing Initiative to Northern Ontario: (a) what was the (i) total number of approved projects, (ii) total number of approved housing units, (iii) total dollar value of each housing project (iv) dollar value of the federal contribution of each housing project, (v) dollar value of any other contributor of each housing project; (b) what is the breakdown of each part in (a) by (i) municipality, (ii) federal electoral constituency; and (c) what are the details of all applications in (a), including (i) project description, (ii) number of approved units, (iii) date the application was submitted to the Canada Mortgage and Housing Corporation, (iv) date the project was announced publicly? |
| Q-21832 — December 13, 2023 — Mrs. Hughes (Algoma—Manitoulin—Kapuskasing) — With regard to the Wahpeton New School Project proposal, since January 2023: (a) what meetings and consultations have the Minister for Crown-Indigenous Relations and the Minister for Indigenous Services had regarding the need for a new community school; (b) what services has the department offered to help Wahpeton with funding, planning, and completion of a new community school; (c) what interim measures has the government provided to Wahpeton Dakota Nation to ensure students can continue in-class learning; (d) does the government intend to fund and complete a new community school in Wahpeton; (e) for what reasons has the government not proceeded with this project; and (f) by what date does the government expect construction to begin on a new community school? |
| Q-21842 — December 13, 2023 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the government’s agreement with Stellantis-LG Energy Solutions (LGES) related to electric-vehicle battery production: (a) were any consultants or external advisors used by the government related to the deal or the negotiations, and, if so, what are the details of each, including (i) who, (ii) the amount of the contract, if applicable, (iii) the description of goods or services provided, (iv) the reason that the consultant or advisor was chosen; and (b) were any bonuses or performance awards awarded to any individuals for their work on the agreement, and, if so, (i) how many people received such bonuses or performance awards, (ii) what was the total amount paid out in such bonuses or performance awards? |
| Q-21852 — December 13, 2023 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to the Sectoral Workforce Solutions Program: (a) how much money has been distributed through the program to date; (b) how many funding applications were received through the program; (c) of the funding applications, how many were granted; (d) what is the total amount distributed through the program to date by province or territory where the applicant is based out of; (e) what are the details of all funding provided to date including, for each, the (i) applicant, (ii) date the money was provided, (iii) amount of funding (iv) type of funding (grant, repayable loan, etc.), (v) purpose of the funding, (vi) project summary; (f) what accountability mechanisms are in place to ensure that funds distributed through the program are used as intended; and (g) have the accountability mechanisms in (f) determined that any funding has not been used appropriately, and, if so, what are the details of each such instance including the name of the recipient and what action was taken by the government in response? |
| Q-21862 — December 13, 2023 — Ms. Rempel Garner (Calgary Nose Hill) — With regard to cancellation fees or similar types of fees for items and services that were booked but not used, since January 1, 2020, and broken down by department, agency, and government entity: (a) what was the total amount spent in cancellation fees, broken down by year; and (b) what are the details of each such instance, including, for each, the (i) vendor, (ii) cost to the government related to the cancellation, (iii) reason for the cancellation, (iv) description, including quantity, of items cancelled (e.g. hotel room, conference hall, car rental, etc.) (v) location of the vendor, (vi) date the items were originally booked for? |
| Q-21872 — December 13, 2023 — Mr. Leslie (Portage—Lisgar) — With regard to the Minister of Environment and Climate Change’s trip to Dubai to attend COP28: (a) what was the Minister’s detailed itinerary on the trip; and (b) what are the details of all meetings attended by the Minister, including, for each, the (i) date, (ii) time, (iii) location, (iv) list of attendees, including the organization represented by each attendee, (v) agenda items, (vi) topics discussed? |
| Q-21882 — December 13, 2023 — Mr. Leslie (Portage—Lisgar) — With regard to Canada's Climate Change Ambassador trip to Dubai to attend COP28: (a) what was the Ambassador’s detailed itinerary on the trip; and (b) what are the details of all meetings attended by the Ambassador, including, for each, the (i) date, (ii) time, (iii) location, (iv) list of attendees, including the organization represented by each attendee, (v) agenda items, (vi) topics discussed? |
| Q-21892 — December 13, 2023 — Mrs. Goodridge (Fort McMurray—Cold Lake) — With regard to the government’s Draft Federal Offset Protocol: Reducing Enteric Methane Emissions from Beef Cattle: (a) has the government analyzed whether the proposal will lead to higher beef prices for consumers, and, if so, (i) who conducted the analysis, (ii) what were the findings; (b) what measures are in place, if any, to ensure that the proposal will not lead to higher beef prices for consumers; (c) what are the projected government expenditures related to (i) establishing the program, (ii) the annual costs associated with operating the program; and (d) how many government employees or full-time equivalents will be working on the program? |
| Q-21902 — December 13, 2023 — Mrs. Goodridge (Fort McMurray—Cold Lake) — With regard to meetings involving the government about safe supply, safer supply, pharmaceutical alternatives to the toxic, illegal or illicit drug supply, pharmaceutical grade medication as an alternative to the toxic, illegal or illicit drug supply, and medications for substance use disorder and to provide pharmaceutical alternatives to the contaminated illegal or illicit drug supply: what are the details of meetings over the last five years between government and pharmaceutical companies, government and opioid manufacturers, government and lobby companies, and government and stakeholders, including, for each, the (i) date, (ii) location, (iii) type and purpose of the meeting, (iv) names of the organizations represented, (v) names and titles of the individuals in attendance, including both government officials and other attendees? |
| Q-21912 — December 13, 2023 — Mrs. Goodridge (Fort McMurray—Cold Lake) — With regard to the government's efforts in Indigenous health and substance use treatment facilities: (a) How many treatment facilities currently exist on Indigenous reserves; (b) what are the details of each facility, including, (i) the First Nation (ii) the location and address, (iii) the name of the facility, (iv) the year it was built, (v) the square footage, (vi) the date of additions or renovations to the facility, (vii) the current number of beds or spaces broken down by inpatient and outpatient treatment, (viii) current staffing and patient level, (ix) the maximum staffing and patient capacity level, (x) whether it’s currently operating understaffed or under the maximum possible; (c) how frequently does the government receive updates or reports from these government-funded treatment facilities regarding their performance and success in meeting specified criteria; and (d) when was the last time such a report or update was received, broken down by each facility it was received from? |
| Q-21922 — December 13, 2023 — Mr. Green (Hamilton Centre) — With regard to audits done by Canada Revenue Agency, since 2015 and broken down by year, number of audits and size of audit: how many audits were either paused or cancelled following contact from an individual representing a company worth over $1 million annually? |
| Q-21932 — December 13, 2023 — Mr. Green (Hamilton Centre) — With regard to any polling data obtained by the Privy Council Office concerning artificial intelligence, since January 1, 2023: (a) what are the details of all polling conducted, including (i) who conducted the poll, (ii) the start and end dates of when the poll was conducted, (iii) the number of participants, (iv) the questions asked, (v) the results of the poll, (v) the value of the contract related to the poll? |
| Q-21942 — December 13, 2023 — Ms. Collins (Victoria) — With regard to any polling data obtained by the Privy Council Office concerning grocery affordability, since January 1, 2023: (a) what are the details of all polling conducted, including (i) who conducted the poll, (ii) the start and end dates of when the poll was conducted, (iii) the number of participants, (iv) the questions asked, (v) the results of the poll, (vi) the value of the contract related to the poll? |
| Q-21952 — December 13, 2023 — Mr. Bachrach (Skeena—Bulkley Valley) — With regard to the Pacific Salmon Strategy Initiative: (a) for the $33.5 million that has been disbursed under the Conservation and Stewardship pillar, (i) what specific projects were funded, (ii) what organization or agency received the funding, (iii) what are the project deliverables, (iv) what is the project’s timeline; (b) for the $28.4 million that has been disbursed under the Salmon Enhancement pillar, (i) what specific projects were funded, (ii) what organization or agency received the funding, (iii) what are the project deliverables, (iv) what is the project’s timeline; (c) for the $33.0 million that has been disbursed under the Harvest Transformation pillar, (i) what specific projects were funded, (ii) what organization or agency received the funding, (iii) what are the project deliverables, (iv) what is the project’s timeline; and (d) for the $8.4 million that has been disbursed under the Integration and Collaboration pillar, (i) what specific projects were funded, (ii) what organization or agency received the funding, (iii) what are the project deliverables, (iv) what is the project’s timeline? |
| Q-21962 — December 13, 2023 — Mr. Bachrach (Skeena—Bulkley Valley) — With regard to any polling data obtained by the Privy Council Office concerning pharmacare, since January 1, 2023: (a) what are the details of all polling conducted, including (i) who conducted the poll, (ii) the start and end dates of when the poll was conducted, (iii) the number of participants, (iv) the questions asked, (v) the results of the poll, (vi) the value of the contract related to the poll? |
| Q-21972 — December 13, 2023 — Mr. Bachrach (Skeena—Bulkley Valley) — With regard to any polling data obtained by the Privy Council Office or the Department of Fisheries, Oceans and the Canadian Coast Guard concerning open net-pen aquaculture in British Columbia, since January 1, 2023: (a) what are the details of all polling conducted, including (i) who conducted the poll, (ii) the start and end dates of when the poll was conducted, (iii) the number of participants, (iv) the questions asked, (v) the results of the poll, (vi) the value of the contract related to the poll? |
| Q-21982 — December 13, 2023 — Ms. Kwan (Vancouver East) — With regard to federal housing investments, between February 1, 2006, and October 1, 2015: (a) how much federal funding was provided to support the construction of non-profit or community housing and how many units were developed broken down (i) by province/territory, (ii) by year; (b) how much federal funding was provided to support the construction of cooperative housing and how many units were developed broken down by (i) province or territory, (ii) year; (c) how much federal funding was provided to support the construction of purpose-built rental housing and how many units were developed broken down by (i) province or territory, (ii) year; (d) how much federal funding was provided to support the construction of housing dedicated to First Nations, Inuit, or Métis communities or delivered to Indigenous-led housing providers and how many units were developed broken down by (i) province or territory, (ii) year; (e) how much federal funding was provided to support the construction of single and multi-family homes and how many units were developed broken down by (i) province or territory, (ii) year? |
| Q-21992 — December 13, 2023 — Mr. Bachrach (Skeena—Bulkley Valley) — With regard to testimony from Veterans Affairs Canada (VAC) at the Standing Committee on Veterans Affairs on December 12, 2023: (a) what are the details of all committees created to review research and policy and provide advice to senior staff, including (i) the title of the committee, (ii) committee membership, (iii) the specific topic or focus of the committee, (iv) the dates of meetings held in the last 18 months, (v) conclusions or advice provided to the Minister of Veterans Affairs; (b) how many times have the committees in (a) discussed matters relating to (i) women’s reproductive health, (ii) sex-specific illnesses and injuries, (iii) illnesses and injuries impacting Veterans’ offspring, (iv) women-specific uniforms and equipment, (v) intimate partner violence among Veterans, (vi) barriers to accessing VAC services for victims of the LGBT Purge, (vii) survivor pensions for Veterans marrying after age 60, (viii) the Merlo-Davidson class action settlement agreement, (ix) groups representing LGBTQI+ and women Veterans, (x) groups advocating for better health outcomes for Veterans; (c) how do the committees in (a) solicit input from other organizations including (i) the Canadian Armed Forces (CAF), (ii) the Department of National Defense (DND), (iii) groups representing LGBTQI+ and women Veterans; and (d) how do the committees in (a) share their findings with organizations including (i) the CAF, (ii) the DND, (iii) groups representing LGBTQI+ and women Veterans? |
| Q-22002 — December 13, 2023 — Ms. Kwan (Vancouver East) — With regard to the Canada Border Security Agency’s management of immigration detention: what is the title, location, and address of each facility used for immigration detention in Canada, and for each of these facilities (i) how many detainees are currently incarcerated therein, (ii) what are the reasons for detention ranked from most to least common, (iii) what percentage of detainees are deemed ‘high-risk’, ‘dangerous’, or flight risks, (iv) what percentage of detainees are refugee claimants or asylum seekers, (v) what percentage of detainees are under 18 years of age, (vi) what is the median and mean time period of incarceration, (vii) what is the longest period of ongoing incarceration of any detainee, (viii) have immigration detainees been subject to segregation or solitary confinement at any point after March 1, 2020, and, if so, for how long on average? |
| Q-22012 — December 13, 2023 — Ms. Kwan (Vancouver East) — With regard to the opening of a First Home Savings Account (FHSA): (a) how many licensed FHSA issuers have been approved by the government to date; (b) how many FHSAs have been opened to date; (c) are individuals who own residential property or properties that are not their principle residence considered a first-time home buyer for the purpose of opening an FHSA; and (d) do the individuals in (c) qualify to open an FHSA, and, if so, how many have opened an FHSA? |
Notices of Motions for the Production of Papers |
|
Business of Supply |
|
Government Business |
|
Private Members' Notices of Motions |
|
Private Members' Business |
|
|
|
| 2 Response requested within 45 days |
|